Rasna Therapeutics, Inc. (RASP)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.44 Million USD | -674.95% |
| 2022 | -573.27 Thousand USD | 55.94% |
| 2021 | -1.3 Million USD | 75.67% |
| 2020 | -5.34 Million USD | -470.99% |
| 2019 | -936.38 Thousand USD | 77.03% |
| 2018 | -4.07 Million USD | 8.06% |
| 2017 | -4.43 Million USD | -7025.09% |
| 2016 | -62.22 Thousand USD | -271.35% |
| 2015 | -16.75 Thousand USD | 58.14% |
| 2014 | -40.03 Thousand USD | -646.92% |
| 2013 | -5360.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -95.51 Thousand USD | 35.3% |
| 2024 Q1 | -147.63 Thousand USD | -153.12% |
| 2023 Q2 | -4.29 Million USD | -2502.37% |
| 2023 Q4 | -58.32 Thousand USD | 44.54% |
| 2023 Q1 | -165.17 Thousand USD | -122.49% |
| 2023 FY | -4.44 Million USD | -674.95% |
| 2023 Q3 | -105.16 Thousand USD | 97.55% |
| 2022 Q1 | -274.63 Thousand USD | -23.0% |
| 2022 Q4 | 734.52 Thousand USD | 228.22% |
| 2022 Q2 | 293.99 Thousand USD | 207.05% |
| 2022 FY | -573.27 Thousand USD | 55.94% |
| 2022 Q3 | -572.85 Thousand USD | -294.85% |
| 2021 Q4 | -223.27 Thousand USD | -80.65% |
| 2021 FY | -1.3 Million USD | 75.67% |
| 2021 Q1 | -171.86 Thousand USD | 92.5% |
| 2021 Q3 | -123.59 Thousand USD | 53.6% |
| 2021 Q2 | -266.36 Thousand USD | -54.99% |
| 2020 Q1 | -158.04 Thousand USD | -162.65% |
| 2020 Q4 | -2.29 Million USD | 15.39% |
| 2020 Q3 | -2.7 Million USD | -1317.57% |
| 2020 Q2 | -190.97 Thousand USD | -20.84% |
| 2020 FY | -5.34 Million USD | -470.99% |
| 2019 Q2 | -265.36 Thousand USD | 33.88% |
| 2019 Q4 | -60.17 Thousand USD | 71.28% |
| 2019 FY | -936.38 Thousand USD | 77.03% |
| 2019 Q3 | -209.54 Thousand USD | 21.03% |
| 2019 Q1 | -401.3 Thousand USD | 1.01% |
| 2018 Q3 | -803.96 Thousand USD | 29.75% |
| 2018 Q2 | -1.14 Million USD | 42.88% |
| 2018 Q1 | -2 Million USD | -9.61% |
| 2018 FY | -4.07 Million USD | 8.06% |
| 2018 Q4 | -405.38 Thousand USD | 49.58% |
| 2017 Q1 | -1.35 Million USD | -5.01% |
| 2017 Q2 | -947.92 Thousand USD | 30.1% |
| 2017 Q4 | -1.82 Million USD | -50.61% |
| 2017 Q3 | -1.21 Million USD | -28.02% |
| 2017 FY | -4.43 Million USD | -7025.09% |
| 2016 Q3 | -55.19 Thousand USD | -2929.58% |
| 2016 Q4 | -1.29 Million USD | -2239.48% |
| 2016 Q2 | -1822.00 USD | 56.94% |
| 2016 FY | -62.22 Thousand USD | -271.35% |
| 2016 Q1 | -4231.00 USD | -333.95% |
| 2015 Q1 | -3672.00 USD | -7.06% |
| 2015 FY | -16.75 Thousand USD | 58.14% |
| 2015 Q4 | -975.00 USD | 68.51% |
| 2015 Q2 | -6559.00 USD | -78.62% |
| 2015 Q3 | -3096.00 USD | 52.8% |
| 2014 FY | -40.03 Thousand USD | -646.92% |
| 2014 Q1 | -14.21 Thousand USD | -90.5% |
| 2014 Q2 | -3491.00 USD | 75.44% |
| 2014 Q3 | -14.86 Thousand USD | -325.78% |
| 2014 Q4 | -3430.00 USD | 76.92% |
| 2013 FY | -5360.00 USD | 0.0% |
| 2013 Q2 | -4305.00 USD | 0.0% |
| 2013 Q4 | -7463.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -232.667% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 36.379% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 108.385% |
| Nascent Biotech, Inc. | -2.08 Million USD | -112.797% |
| Rebus Holdings, Inc. | -1.02 Million USD | -335.543% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 106.821% |
| Qrons Inc. | -789.34 Thousand USD | -462.811% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -602.48% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 92.903% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -969.256% |
| Skye Bioscience, Inc. | -37.64 Million USD | 88.199% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.074% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 32.444% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1524.909% |
| SQZ Biotechnologies Company | -79.46 Million USD | 94.409% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -53.594% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -144.025% |
| Mesoblast Limited | -87.95 Million USD | 94.949% |
| Marizyme, Inc. | -65.34 Million USD | 93.202% |
| Genus plc | 7.9 Million USD | 156.235% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 59.212% |
| Pharming Group N.V. | -10.54 Million USD | 57.883% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -104.743% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -19.737% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 49.768% |
| ContraFect Corporation | -65.15 Million USD | 93.181% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 9.077% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -157.172% |
| IMV Inc. | -36.48 Million USD | 87.824% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 44.88% |
| MultiCell Technologies, Inc. | -380.07 USD | -1168772.839% |
| ONE Bio Corp. | 8.67 Million USD | 151.201% |
| Accustem Sciences Inc. | -3.74 Million USD | -18.581% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 91.406% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -250.597% |
| Q BioMed Inc. | -2.05 Million USD | -116.488% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -19.007% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -86.593% |
| Biomind Labs Inc. | -1.21 Million USD | -265.846% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 92.562% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -43.226% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 43.787% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -127.91% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -29564.363% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 72.009% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 23.632% |
| GB Sciences, Inc. | -1.36 Million USD | -226.255% |
| Alpha Cognition Inc. | -13.77 Million USD | 67.744% |
| HST Global, Inc. | -146.21 Thousand USD | -2938.462% |
| CSL Limited | 2.64 Billion USD | 100.168% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -153.169% |
| Halberd Corporation | -79.67 Thousand USD | -5475.751% |
| Enzolytics Inc. | -2.17 Million USD | -104.083% |
| Agentix Corp. | -1.37 Million USD | -223.279% |
| Resverlogix Corp. | -3.61 Million USD | -23.062% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -40.08% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.494% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4633.199% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 164.156% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -11.818% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -46.806% |
| AVAX Technologies, Inc. | -6.41 Million USD | 30.733% |
| Zenith Capital Corp. | -10.59 Million USD | 58.073% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.347% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -19014.254% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -7.154% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -7250.248% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -121.56% |
| Kadimastem Ltd | -3.3 Million USD | -34.321% |
| Helix BioMedix, Inc. | -1.05 Million USD | -320.672% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -16.327% |
| BioStem Technologies, Inc. | -8.48 Million USD | 47.63% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -906.535% |
| LadRx Corporation | 400.44 Thousand USD | 1209.405% |
| Cell Source, Inc. | -5.32 Million USD | 16.513% |
| Regen BioPharma, Inc. | 1.02 Million USD | 534.05% |
| Regen BioPharma, Inc. | 1.02 Million USD | 534.05% |
| NovAccess Global Inc. | -4.76 Million USD | 6.849% |
| Affymax, Inc. | -14.42 Million USD | 69.2% |
| Itoco Inc. | -1.86 Million USD | -137.696% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -166.179% |
| Mobile Lads Corp. | -2.26 Million USD | -96.286% |
| CytoDyn Inc. | -49.84 Million USD | 91.087% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -5521.114% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1847.396% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -371.843% |
| SYBLEU INC | -180.3 Thousand USD | -2363.914% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -175.466% |
| International Stem Cell Corporation | -131 Thousand USD | -3291.248% |
| Bioxytran, Inc. | -4.28 Million USD | -3.797% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -8085.685% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -75.577% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 90.759% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -110.148% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -468.909% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -40.232% |
| Neutra Corp. | -233.46 Thousand USD | -1802.87% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 78.106% |
| PureTech Health plc | -65.69 Million USD | 93.238% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 79.11% |
| IXICO plc | -1.17 Million USD | -277.125% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 55.248% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 92.224% |
| CSL Limited | 2.64 Billion USD | 100.168% |
| Cellectis S.A. | -103.17 Million USD | 95.694% |